R1 Rcm Inc Stock Price, News & Analysis

R1 RCM reported its Q2 2022 results, highlighting revenue of $391.9 million, a 10.9% increase from the previous year. However, the company experienced a GAAP net loss of $20.4 million, primarily due to $74.4 million of expenses related to the Cloudmed acquisition. Adjusted EBITDA rose to $87.2 million, marking a 10.7% increase year-over-year. For 2022, R1 expects revenue between $1,850 million and $1,870 million and adjusted EBITDA of $470 million to $480 million.

R1 RCM Inc. (NASDAQ: RCM) announced it will release its financial results for the second quarter of 2022 on August 3, 2022, before market open. The management team will host a conference call at 8:00 a.m. ET on the same day to discuss results and future outlook. Interested participants can join via phone or through a live webcast on the company’s website. R1 RCM specializes in technology-driven solutions designed to enhance the patient experience and improve the financial performance of healthcare providers.

R1 RCM (NASDAQ: RCM) announced a 10-year exclusive partnership with Sutter Health to provide revenue cycle management services. This collaboration aims to enhance patient access and reduce operational costs, potentially yielding $400 million in savings over the decade. Approximately 1,150 Sutter employees will transition to R1 with comparable roles and benefits, maintaining jobs in California. This agreement emphasizes R1's expertise in improving healthcare financial performance while addressing rising costs and inflation concerns.

On June 21, 2022, R1 RCM Inc. (NASDAQ:RCM) announced the granting of equity awards under its 2022 Inducement Plan as part of its acquisition of Cloudmed, which was finalized on the same day. The awards include 151,286 performance-based restricted stock units (PBRSUs) to President Lee Rivas and a total of 2,895,826 PBRSUs and 126,072 restricted stock units (RSUs) to 123 Cloudmed employees. The PBRSUs will vest based on performance over a three-year period, with vesting conditions tied to corporate financial objectives.

R1 RCM Inc. (NASDAQ: RCM) has completed its acquisition of Cloudmed, aiming to enhance its revenue cycle management platform and accelerate digital transformation in healthcare. The merger positions R1 as a leading partner for healthcare providers, combining expertise and innovative technology. New appointments to the Board of Directors are expected to drive growth and innovation. A conference call is scheduled for June 27 to discuss the business outlook and updated guidance following the acquisition.

R1 RCM Inc. (NASDAQ: RCM) reported strong financial results for Q1 2022, with revenue of $385.7 million, a 12.6% increase year-over-year. GAAP net income rose to $29.4 million, reflecting a 14.0% growth. Adjusted EBITDA reached $89.3 million, up 11.1%. The company’s acquisition of Cloudmed is on track for completion by the end of June 2022, expected to enhance stakeholder value. R1's 2022 revenue outlook is set between $1,660 million and $1,700 million.

R1 RCM (NASDAQ:RCM) has partnered with ScionHealth to provide exclusive revenue cycle management services for its 61 long-term acute care hospitals. The agreement aims to enhance patient outcomes through advanced technology and analytics, helping ScionHealth achieve better financial results and operational efficiency. R1's integrated solutions will enable standardization across ScionHealth's facilities, driving improved financial performance and patient experiences. This collaboration reflects both organizations' commitment to high-quality healthcare and technological innovation.

MURRAY, Utah, May 03, 2022 (GLOBE NEWSWIRE) -- R1 RCM (NASDAQ: RCM), a leader in technology solutions for healthcare, announced participation in two investor conferences. The first is the Bank of America Securities 2022 Healthcare Conference on May 11, 2022, at 3:20 PM PT, followed by the RBC Capital Markets Global Healthcare Conference on May 17, 2022, at 9:00 AM ET. Live webcasts will be available on R1’s Investor Relations site, with replays accessible for 90 days.

R1 RCM (NASDAQ: RCM) will announce its financial results for Q1 2022 on May 9, 2022, prior to market opening. A conference call is scheduled for the same day at 8:00 a.m. ET, which shareholders can join by dialing 888-330-2022. R1 RCM specializes in technology-driven solutions aimed at enhancing patient experiences and improving financial performance for healthcare providers. They focus on boosting net patient revenue while streamlining operational costs.